RC
ABMD

RegentAtlantic Capital’s Abiomed Inc ABMD Stock Holding History

RegentAtlantic Capital’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-867
Closed -$215K – 712
2022
Q2 		$215K Buy
+867
New +$234K 0.01% 624

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return

RegentAtlantic Capital's ABMD Position: Q3 2022 in Review

RegentAtlantic Capital sold out of Abiomed Inc (ABMD) in Q3 2022, closing a stake of 867 shares — an estimated $215K sold.

RegentAtlantic Capital first reported a position in ABMD in Q2 2022 and held it in 1 quarter. The position peaked at $215K in Q2 2022. 517 funds tracked by Wall St. Rank hold ABMD as of Q3 2022.

  • RegentAtlantic Capital reported no remaining Abiomed Inc position as of Q3 2022 after selling out during the quarter.
  • RegentAtlantic Capital sold 867 Abiomed Inc shares in Q3 2022, an estimated $215K.
  • RegentAtlantic Capital first reported a position in Abiomed Inc in Q2 2022 and held it in 1 quarter.
  • RegentAtlantic Capital's Abiomed Inc position peaked at $215K in Q2 2022.
  • 517 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2022.

Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.